Johnson and Johnson executive splits for the corner office at Itamar Medical

Former J&J executive joins Itamar Medical as CEO
Gilad Glick will leave his job as head of Johnson & Johnson’s (NYSE:JNJ) global cardiology division to become the CEO of Itamar Medical in July.

The Caesarea, Israel-based medical device maker said current CEO, Dov Rubin, will step down after serving for 5 years. The company calls this a "pivotal point of transitionally into an accelerated commercial stage."

Glick joined Biosense Webster while it was still a small start up, before it was sold to Johnson and Johnson as part of company’s cardiovascular division. While at Johnson and Johnson, Glick served as VP of worldwide sales and marketing and as a senior member of the Biosense team.
Read more

Interim CEO step up, VP of finance steps down at Vision-Sciences
Vision-Sciences Inc. (NSDQ:VSCI) appointed an interim CEO to replace Cynthia Ansari, who stepped down after 2 years at the job. Howard I. Zauberman was appointed based on his 30 years of experience in the medical device industry. The Orangeburg, S.C.-based endoscopic device maker also announced resignation of Keith Darragh, the company’s VP of finance and accounting officer.
Read more

New VP of global sales and marketing at Misonix

Misonix (NSDQ:MSON) appointed Scott Ludecker VP of global sales and marketing. He joins the company from the same role at BioMimetic Therapeutics. Ludecker has more than 20 years experience in the global medical device industry, most recently at BioMimetic and Small Bone Innovations. According to the April 8 offer letter, Ludecker will receive a base salary of $200,000 and report directly to CEO Michael McManus, Jr.
Read more

Third Rock Ventures pulls in industry executives
Venture capital firm Third Rock recently appointed several new executives from large pharmaceutical and medical device companies.

The Boston, Mass.-based VC named James Geraghty as entrepreneur-in-residence. Geraghty comes to Third Rock with 20 years experience at Genzyme Corporation. Steven Paul will be stepping up his role as a venture partner. He is a former Lilly Research Labs president and director of the Helen & Robert Appel Institute for Alzheimer’s Research at Weill Cornell Medical College. Daniel Lynch, former CEO of ImClone Systems, will transition from entrepreneur-in-residence to a venture partner. John Maraganore, CEO of Alnylam, also joined the Third Rock as a venture partner.
Read more

New CEO joins Accumed Radial Systems
Michael Pisano joined Accumed Radial Systems as president and CEO. Pisano will lead the the newly formed wholly owned subsidiary of Accumed Systems, Inc. The newly formed Accumed Radial Systems was created after successful roll out of several transradial procedures by Accumed Systems, which decided to create the subsidiary to focus solely on this market. Pisano formerly worked as CEO of NextGen Group.
Read more